Shares of Agenus Inc. AGEN plunged 58.8% on Jul 18 after the corporate introduced the result of its end-of-phase II (EOP2) assembly with the FDA concerning the accelerated growth of its immunotherapy mixture botensilimab (BOT) and balstilimab (BAL).
The BOT/BAL mixture is being studied for the therapy of grownup sufferers with relapsed/refractory microsatellite secure colorectal most cancers (r/r MSS CRC) with no energetic liver metastases.
The FDA discouraged the accelerated approval pathway for the BOT/BAL mixture in r/r MSS CRC. As per the regulatory physique, the target response price (ORR) noticed within the part II examine may not convert to survival profit.
AGEN introduced top-line interim information from a part II examine that evaluated the BOT/BAL mixture in r/r MSS CRC. The interim information demonstrated the perfect exercise at 75 mg BOT/240mg BAL mixture, which led to an ORR of 19.4%. Additionally, on the similar dose, 90% of the sufferers have been alive.
Shares of Agenus have plunged 55.9% thus far this yr in contrast with the business’s decline of 1.4%.
Picture Supply: Zacks Funding Analysis
Per the press launch, the corporate has reached an settlement with the FDA on the proposed dose of the BOT/BAL mixture for a part III examine. The agreed dosing of the BOT/BAL mixture routine is BOT (75mg) as soon as each six weeks for as much as 4 doses together with BAL (240mg) as soon as each two weeks for as much as two years.
The FDA has additionally proposed to incorporate a BOT monotherapy arm within the part III examine. AGEN is presently on the lookout for a companion in the USA to conduct the part III examine.
Botensilimab is AGEN’s proprietary, novel and multifunctional CTLA-4 investigational antibody to deal with chilly tumors that haven’t traditionally responded to standard-of-care or investigational therapies.
Other than CRC, the BOT/BAL mixture has additionally demonstrated scientific exercise in different most cancers indications, equivalent to lung most cancers, melanoma and pancreatic cancers.
Zacks Rank & Shares to Take into account
Agenus presently carries a Zacks Rank #3 (Maintain).
Some top-ranked shares within the biotech sector are ANI Prescribed drugs, Inc. ANIP, Adaptive Biotechnologies Company ADPT and RAPT Therapeutics, Inc. RAPT, every carrying a Zacks Rank #2 (Purchase) at current. You may see the entire checklist of immediately’s Zacks #1 Rank (Sturdy Purchase) shares right here.
Up to now 60 days, estimates for ANI Prescribed drugs’ 2024 earnings per share have improved from $4.41 to $4.44. Earnings per share estimates for 2025 have improved from $4.85 to $5.42. 12 months so far, shares of ANIP have jumped 11.3%.
ANIP’s earnings beat estimates in every of the trailing 4 quarters, the typical shock being 53.90%.
Up to now 60 days, estimates for Adaptive Biotechnologies’ 2024 loss per share have narrowed from $1.30 to $1.29, whereas loss per share estimates for 2025 have narrowed from $1.08 to $1.02. 12 months so far, shares of ADPT have misplaced 13.6%.
ADPT’s earnings beat estimates in two of the trailing 4 quarters, assembly the identical as soon as and lacking on the remaining event, the typical shock being 0.65%.
Up to now 60 days, estimates for RAPT Therapeutics’ 2024 loss per share have narrowed from $2.94 to $2.93. Loss per share estimates for 2025 have narrowed from $2.06 to $2.05. 12 months so far, shares of RAPT have plunged 86.2%.
RAPT’s earnings beat estimates in two of the trailing 4 quarters whereas lacking the identical on the remaining two events, the typical shock being 3.19%.
Need the newest suggestions from Zacks Funding Analysis? At this time, you possibly can obtain 7 Greatest Shares for the Subsequent 30 Days. Click on to get this free report
Agenus Inc. (AGEN) : Free Inventory Evaluation Report
ANI Prescribed drugs, Inc. (ANIP) : Free Inventory Evaluation Report
Adaptive Biotechnologies Company (ADPT) : Free Inventory Evaluation Report
Rapt Therapeutics (RAPT) : Free Inventory Evaluation Report
